The Next Giant Leap: How China’s Akeso is Transforming Cancer Treatment
Akeso introduces ivonescimab, a groundbreaking cancer drug, extending patient survival without disease progression to over 11 months, outperforming Keytruda's 5.8 months. Ivonescimab's success represents a significant advancement in cancer treatment,…